{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-230765","form_type":"8-K","ticker":null,"cik":"0001769804","company_name":"Augmedix, Inc.","filed_at":"2024-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.544398+00:00","generated_at":"2026-05-30T22:43:03.458635+00:00","sec_items":["1.02","2.01","3.01","3.03","5.03","5.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Commure completes acquisition of Augmedix for $2.35/share; stock delisted","bullets":["Merger completed Oct 2, 2024; Augmedix stockholders receive $2.35 per share in cash.","Total consideration payable to equityholders approximately $139 million, funded by equity and cash.","Augmedix becomes wholly owned subsidiary of Commure; common stock delisted from Nasdaq.","All outstanding warrants terminated for no consideration; loan agreement repaid in full.","Entire board resigned; Tanay Tandon named CEO, Daniel Brian CFO/Secretary of surviving company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-230765","json":"https://secwatch.observer/filing/0001193125-24-230765.json","markdown":"https://secwatch.observer/filing/0001193125-24-230765.md","text":"https://secwatch.observer/filing/0001193125-24-230765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/d875756d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:43:03.458635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a5785e922","claim":"Robert Faulkner resigned as Director at Augmedix, Inc..","evidence_excerpt":"As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1fefd4aa2f","claim":"Jason Krikorian resigned as Director at Augmedix, Inc..","evidence_excerpt":"As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"36c9899343","claim":"Daniel Brian was appointed as Chief Financial Officer, Treasurer and Secretary at Augmedix, Inc..","evidence_excerpt":"Effective at the completion of the Merger, Tanay Tandon became President and Chief Executive Officer, Daniel Brian became Chief Financial Officer, Treasurer and Secretary and Deepika Bodapati became Chief Operating Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer, Treasurer and Secretary"}],"fact_type":"executive_change"},{"claim_id":"7edf5faea6","claim":"Margie L. Traylor resigned as Director at Augmedix, Inc..","evidence_excerpt":"As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8c1bb39cb3","claim":"Ian Shakil resigned as Director at Augmedix, Inc..","evidence_excerpt":"As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a4d81fee0f","claim":"Roderick H. O’Reilly resigned as Director at Augmedix, Inc..","evidence_excerpt":"As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a76ae80ac6","claim":"Tanay Tandon was appointed as President and Chief Executive Officer at Augmedix, Inc..","evidence_excerpt":"Effective at the completion of the Merger, Tanay Tandon became President and Chief Executive Officer, Daniel Brian became Chief Financial Officer, Treasurer and Secretary and Deepika Bodapati became Chief Operating Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c4098555c8","claim":"Emmanuel Krakaris resigned as Director at Augmedix, Inc..","evidence_excerpt":"As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e4f0c22f0a","claim":"Laurie A. S. McGraw resigned as Director at Augmedix, Inc..","evidence_excerpt":"As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f2d9dd1912","claim":"William J. Febbo resigned as Director at Augmedix, Inc..","evidence_excerpt":"As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fbbe515f73","claim":"Daniel Brian was appointed as sole director at Augmedix, Inc..","evidence_excerpt":"At the Effective Time, and upon the completion of the Merger, Daniel Brian was appointed as sole director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"sole director"}],"fact_type":"executive_change"},{"claim_id":"fd9aa91888","claim":"Deepika Bodapati was appointed as Chief Operating Officer at Augmedix, Inc..","evidence_excerpt":"Effective at the completion of the Merger, Tanay Tandon became President and Chief Executive Officer, Daniel Brian became Chief Financial Officer, Treasurer and Secretary and Deepika Bodapati became Chief Operating Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"ba3fe61a2794b775850f4d95dc3a0683be7ff754","claim":"Augmedix, Inc. underwent a change of control involving Commure, Inc. for $2.35 in cash (closed 2024-10-02).","evidence_excerpt":"Time”), each issued and outstanding share of Augmedix’s common stock, par value $0.0001 per share (“Common Stock”), was canceled and converted into the right to receive $2.35 in cash, without interest (the “Merger Consideration”) and subject to any applicable tax withholdings, subject to certain exceptions set forth in the Merger Agreement. Harrigan","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Commure, Inc."},{"label":"Consideration","value":"$2.35 in cash"},{"label":"Closing","value":"2024-10-02"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}